Our research applies an entirely new class of biomarkers based on a new understanding of DNA
Our studied mutations are unlike any other known, inherited genetic markers, based on where they are found in the DNA, and their ability to both predict disease as well as potential strategies to prevent disease. These biomarkers show great potential for use in disease prevention because they can be influenced by certain life exposures.
Our first discovered biomarker was the KRAS-variant, which is:
(1) an inherited, genetic marker that has significant implications for women’s health
(2) a predictor of breast, ovarian and lung cancer
(3) a biomarker that identifies women who can be protected from cancer by staying on estrogen, and that identifies patients who will respond uniquely to cancer treatment
We are applying other mutations like the KRAS-variant to better understand other diseases, such as autoimmunity.
MiraKind is collecting research subjects to be involved in research studies to find answers. Please join!
Current research questions include:
- What is the Role of Hormone Replacement Therapy in Breast Cancer Risk?
- What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence disease risk for individuals with identified the KRAS-variant?
- For individuals with the KRAS-variant, what are their risks for developing cancer that can be modified?
- How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
- Learn more about our current open study here